Fri, Nov 21, 2014, 7:17 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Amylin Pharmaceuticals, Inc. Message Board

  • skinz4q skinz4q Feb 22, 2006 9:34 PM Flag

    Keep It Cool!

    For those who thought I was trying to bash AMLN, you're dead wrong! Since I recently found out that I have diabetes, I've been looking for a way to cover the cost of new drugs such as Byetta, when and if I need it. I did the same thing several years ago with oil. I knew that both heating oil and gasoline were going to soar after Bush was appointed president, so I loaded up on oil stocks in the belief that they would pay me back for the higher costs of buying their products. Now, I'm doing the same thing with AMLN. If I make enough money on the stock to pay for my supply of their products, I'll be happy to pay whatever outrageous price they want to charge me. Maybe it's crazy thinking, but it works for me. I look at the products I need or want and but or sell the stocks accordingly. Bought Toyota a few years ago and now own a beautiful Lexus. As far as I'm concerned, the company gave me the car as a "gift" for owning their stock. (I'm glad I didn't want a GM or Ford car!) I bought some Boeing a few years ago... still waiting for it to go up enough to buy one of their business jets.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • That is correct, AMLN reports all of the revenues and half the profits. the other half is treated as a marketing/sales expense and is deductible.

      In Europe AMLN receives 20% of the profits.

      IMHO a mutiple of 6 to 7 on total sales is probably more realistic.

    • If you are correct tinkie winkie, than that is certainly a significant difference. One still couldn't value AMLN at 8 times revenue, if others have the same valuation but are not sharing profits. But, yes, very big difference from what I suggested. Thanks for the clarification.

      Best regards,
      Geoff

    • eubank,

      I'm with you all the way, but don't forget that half the Byetta revs do have to be split with Lilly. I also believe 3 billion is realistic, but obviously 8 times half that is 12 billion. Add Symlin sales, and perhaps a fair PPS is 125-150...still a "screaming buy" as bridgeofsighs would say.

      Best to all,
      Geoff

    • Thank you, amlnt, I think you might mean Kelly Close? Her commentary is always outstanding.

      K2

    • Pharmacol Exp Ther. 2002 Mar;300(3):958-66. Related Articles, Links


      A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells.

      Perry T, Lahiri DK, Chen D, Zhou J, Shaw KT, Egan JM, Greig NH.

      Section of Drug, Design, and Development, Laboratory of Neuroscience, Gerontology Research Center, National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224, USA. perryt@grc.nia.nih.gov

      The insulinotropic hormone glucagon-like peptide-1 (7-36)-amide (GLP-1) has potent effects on glucose-dependent insulin secretion, insulin gene expression, and pancreatic islet cell formation and is presently in clinical trials as a therapy for type 2 diabetes mellitus. We report on the effects of GLP-1 and two of its long-acting analogs, exendin-4 and exendin-4 WOT, on neuronal proliferation and differentiation, and on the metabolism of two neuronal proteins in the rat pheochromocytoma (PC12) cell line, which has been shown to express the GLP-1 receptor. We observed that GLP-1 and exendin-4 induced neurite outgrowth in a manner similar to nerve growth factor (NGF), which was reversed by coincubation with the selective GLP-1 receptor antagonist exendin (9-39). Furthermore, exendin-4 could promote NGF-initiated differentiation and may rescue degenerating cells after NGF-mediated withdrawal. These effects were induced in the absence of cellular dysfunction and toxicity as quantitatively measured by 3-(4,5-cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide and lactate dehydrogenase assays, respectively. Our findings suggest that such peptides may be used in reversing or halting the neurodegenerative process observed in neurodegenerative diseases, such as the peripheral neuropathy associated with type 2 diabetes mellitus and Alzheimer's and Parkinson's diseases. Due to its novel twin action, GLP-1 and exendin-4 have therapeutic potential for the treatment of diabetic peripheral neuropathy and these central nervous system disorders.

      Cheers,

    • i cant..i could only clip that part for you. protected

    • I got a welcome pack from my diabetes educator when she showed me how to use the pen. In the pack was intsructions on how to contact amlyn/lilly either by phone or internet and they for the time being are sending you a travel pack. They said it would take five to six weeks but mine came in about ten days. It has gel packs that you put in the refrigerator inside the carrying case. They also are available commercially for around fifty dollars.
      I am retired military, and got one pen locally even though express scripts had received a scrip for three pens. The pharmacist called and got a waiver.
      the only problem I have had with express scrips is they sent syringes instead of universal needles, but I also got 30 days supply of needles locally so it is all working. My reading tonight was 124 after having egg plant parmigan for dinner.
      I am an energy investor and can't get used to a stock selling at more than four times cssh flow, so I don't know if the stock is a good buy or not, but the products work and that is what is important.

 

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Foot Locker, Inc.
NYSEFri, Nov 21, 2014 4:00 PM EST
Aruba Networks, Inc.
NasdaqGSFri, Nov 21, 2014 4:00 PM EST